Ionis Pharmaceuticals
IONS
335 hedge funds and large institutions have $6.4B invested in Ionis Pharmaceuticals in 2015 Q4 according to their latest regulatory filings, with 65 funds opening new positions, 98 increasing their positions, 101 reducing their positions, and 39 closing their positions.
75% more funds holding in top 10
Funds holding in top 10: 4 → 7 (+3)
67% more first-time investments, than exits
New positions opened: 65 | Existing positions closed: 39
49% more capital invested
Capital invested by funds: $4.28B → $6.4B (+$2.11B)
7% more funds holding
Funds holding: 314 → 335 (+21)
3% less repeat investments, than reductions
Existing positions increased: 98 | Existing positions reduced: 101
10% less call options, than puts
Call options by funds: $82.9M | Put options by funds: $91.9M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OppenheimerFunds
New York
|
+$68.5M |
| 2 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
+$20M |
| 3 |
EAM
EverPoint Asset Management
Stamford,
Connecticut
|
+$16.2M |
| 4 |
Goldman Sachs
New York
|
+$14.2M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$12.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AllianceBernstein
Nashville,
Tennessee
|
-$47.6M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$33.8M |
| 3 |
GTP
Global Thematic Partners
New York
|
-$31.6M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$30.1M |
| 5 |
Capital Fund Management (CFM)
Paris,
France
|
-$23.6M |
IONS Hedge Fund Activity: Q4 2015 in Review
335 of the 3,824 institutional investors tracked by Wall St. Rank reported a position in Ionis Pharmaceuticals (IONS) for Q4 2015, worth a combined $6.4B — up 49% from $4.28B a quarter earlier.
Buyers outnumbered sellers: 65 funds opened new IONS positions and 39 closed out — a net gain of 26 holders — while 98 added to existing stakes and 101 trimmed.
The largest buyer was OppenheimerFunds, opening a new position worth an estimated $68.5M. The largest seller was AllianceBernstein, cutting an estimated $47.6M.
- 335 institutional investors held Ionis Pharmaceuticals (IONS) as of Q4 2015, up from 314 in Q3 2015.
- Funds reported $6.4B of Ionis Pharmaceuticals stock for Q4 2015, up 49% quarter-over-quarter.
- 65 funds opened new Ionis Pharmaceuticals positions in Q4 2015 and 39 closed out, a net change of +26 holders.
- The largest Ionis Pharmaceuticals buyer in Q4 2015 was OppenheimerFunds, an estimated $68.5M added.
- The largest Ionis Pharmaceuticals seller in Q4 2015 was AllianceBernstein, an estimated $47.6M sold.
Based on aggregated 13F filings for Q4 2015.